151 results on '"Bak, N"'
Search Results
2. Testing a decades’ old assumption: Are individuals with lower sensory gating indeed more easily distracted?
- Author
-
Bak, N., Mann, J., Fagerlund, B., Glenthøj, B.Y., Jepsen, J.R.M., and Oranje, B.
- Published
- 2017
- Full Text
- View/download PDF
3. Construction of type-II SnO2/InGaN nanorods heterostructure toward high photoelectrochemical performance.
- Author
-
Thota, C., Ramu, S., Gangadhara, C., Murali, G., Yang, J. H., Upare, D. P., Bak, N.-H., Kshetri, Y. K., Sohn, Y., Reddeppa, M., and Kim, M.-D.
- Subjects
HETEROJUNCTIONS ,PHOTOCATHODES ,X-ray photoelectron spectroscopy ,NANORODS ,CONDUCTION bands ,INDIUM gallium nitride ,SURFACE states - Abstract
Exploring highly efficient and stable photoelectrode material is essential for high-performance photoelectrochemical (PEC) water-splitting applications. III-nitride semiconductors, particularly InGaN, have been considered as prospective materials for PEC hydrogen evolution. However, their surface states and other recombination centers, which enhance the charge recombination kinetics, are bottlenecks for the high PEC performance. In this work, we report the construction of type-II heterojunction by sputter depositing SnO
2 on InGaN nanorods (NRs) to promote interfacial carrier transport and thereby enhance PEC performance. The energy band offsets at the SnO2 /InGaN NRs interface were analyzed by x-ray photoelectron spectroscopy. Type-II heterojunction was defined at the SnO2 /InGaN NRs interface with a valence band offset of 0.77 eV and conduction band offset of 0.25 eV. The photocurrent density of the SnO2 /InGaN NRs photoanode is 7.09 mA/cm2 at 0.77 V vs Ag/AgCl electrode with 80 nm SnO2 thickness, which is ∼14-fold higher than that of the pristine InGaN NRs photoanode. Furthermore, the applied bias photo-to-current efficiency of SnO2 /InGaN NRs photoanode records 3.36% at 0.77 V vs Ag/AgCl electrode. The enhanced PEC performance is mainly ascribed to the formation of high-quality SnO2 /InGaN NRs heterojunction that enforces the directional charge transfer and substantially boosts the separation of photogenerated electron–hole pairs at the interface of InGaN NRs and SnO2 . Overall, this work sheds light on the promising strategy to design and fabricate III-nitride nanostructures-based photoelectrodes for feasible PEC water-splitting applications. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Mucormycosis in Australia: contemporary epidemiology and outcomes
- Author
-
Clark, Julia, McCormack, Joseph, Looke, David, Playford, E. Geoffrey, Chen, Sharon, Gottlieb, Thomas, Halliday, Catriona, Marriott, Deborah, McMullan, Brendan, Meyer, Wieland, Sorrell, Tania, van Hal, Sebastian, Ananda-Rajah, Michelle, Morrissey, C. Orla, Slavin, Monica, Bak, Narin, Kidd, Sarah, Arthur, Ian, Blyth, Christopher, Heath, Christopher, Kennedy, Karina, Daveson, Kathryn, Morris, Arthur, Chambers, Steve, Kennedy, K.J., Daveson, K., Slavin, M.A., van Hal, S.J., Sorrell, T.C., Lee, A., Marriott, D.J., Chapman, B., Halliday, C.L., Hajkowicz, K., Athan, E., Bak, N., Cheong, E., Heath, C.H., Morrissey, C.O., Kidd, S., Beresford, R., Blyth, C., Korman, T.M., Robinson, J.O., Meyer, W., and Chen, S.C.-A.
- Published
- 2016
- Full Text
- View/download PDF
5. Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study
- Author
-
Keighley, C., Chen, S. C-A., Marriott, D., Pope, A., Chapman, B., Kennedy, K., Bak, N., Underwood, N., Wilson, H. L., McDonald, K., Darvall, J., Halliday, C., Kidd, S., Nguyen, Q., Hajkowicz, K., Sorrell, T. C., Van Hal, S., and Slavin, M. A.
- Published
- 2019
- Full Text
- View/download PDF
6. 2D MXene/ 1D GaN van der Waals heterojunction for self-powered UV photodetector
- Author
-
Thota, C., primary, Murali, G., additional, Dhanalakshmi, R., additional, Reddeppa, M., additional, Bak, N.-H., additional, Nagaraju, G., additional, Kim, S.-G., additional, Modigunta, J. K. R., additional, Park, Y. H., additional, In, Insik, additional, and Kim, M.-D., additional
- Published
- 2023
- Full Text
- View/download PDF
7. ‘No cognitive‐enhancing effect of GLP‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia’: authorsʼ response
- Author
-
Ebdrup, B. H., Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., and Glenthøj, B. Y.
- Published
- 2017
- Full Text
- View/download PDF
8. Professionalising the Supervision Relationship: A Reply to Waghid, Fataar and Hugo
- Author
-
Bak, N.
- Abstract
In this article, I examine three claims that in some senses can hinder the supervisory process rather than facilitate it. These are the claims that the relationship between supervisor and student should be a friendship; that students writing their theses should demonstrate "own voice"; and that students should choose supervisors on the authority of their academic lineage. I shall argue that although these claims are fruitful, we need to be aware of their inherent risks and of the appropriate limits of the key concepts. (Contains 10 notes.)
- Published
- 2011
9. Correlates of late-onset antipsychotic treatment resistance
- Author
-
Fonseca De Freitas, D., primary, Agbedjro, D., additional, Kadra-Scalzo, G., additional, Francis, E., additional, Ridler, I., additional, Pritchard, M., additional, Shetty, H., additional, Segev, A., additional, Casetta, C., additional, Smart, S., additional, Morris, A., additional, Downs, J., additional, Christensen, S., additional, Bak, N., additional, Kinon, B., additional, Stahl, D., additional, Hayes, R., additional, and Maccabe, J., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis
- Author
-
Glenthøj, L. B., Jepsen, J. R. M., Hjorthøj, C., Bak, N., Kristensen, T. D., Wenneberg, C., Krakauer, K., Nordentoft, M., and Fagerlund, B.
- Published
- 2017
- Full Text
- View/download PDF
11. FINANCIAL SECURITY OF THE ENTERPRISE AND THREATS OF ITS LOSS IN THE MODERN ECONOMIC ENVIRONMENT
- Author
-
Marusiak, N., primary and Bak, N., additional
- Published
- 2022
- Full Text
- View/download PDF
12. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality
- Author
-
Slavin, M., van Hal, S., Sorrell, T.C., Lee, A., Marriott, D.J., Daveson, K., Kennedy, K., Hajkowicz, K., Halliday, C., Athan, E., Bak, N., Cheong, E., Heath, C.H., Orla Morrissey, C., Kidd, S., Beresford, R., Blyth, C., Korman, T.M., Owen Robinson, J., Meyer, W., and Chen, S.C.-A.
- Published
- 2015
- Full Text
- View/download PDF
13. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia
- Author
-
Tong, S.Y.C., Lye, D.C., Yahav, D., Sud, A., Robinson, J.O., Nelson, J., Archuleta, S., Roberts, M.A., Cass, A., Paterson, D.L., Foo, H., Paul, M., Guy, S.D., Tramontana, A.R., Walls, G.B., McBride, S., Bak, N., Ghosh, N., Rogers, B.A., Ralph, A.P., Davies, J., Ferguson, P.E., Dotel, R., McKew, G.L., Gray, T.J., Holmes, N.E., Smith, S., Warner, M.S., Kalimuddin, S., Young, B.E., Runnegar, N., Andresen, D.N., Anagnostou, N.A., Johnson, S.A., Chatfield, M.D., Cheng, A.C., Fowler, V.G., Howden, B.P., Meagher, N., Price, D.J., van Hal, S.J., O’Sullivan, M.V. N., Davis, J.S., Tong, S.Y.C., Lye, D.C., Yahav, D., Sud, A., Robinson, J.O., Nelson, J., Archuleta, S., Roberts, M.A., Cass, A., Paterson, D.L., Foo, H., Paul, M., Guy, S.D., Tramontana, A.R., Walls, G.B., McBride, S., Bak, N., Ghosh, N., Rogers, B.A., Ralph, A.P., Davies, J., Ferguson, P.E., Dotel, R., McKew, G.L., Gray, T.J., Holmes, N.E., Smith, S., Warner, M.S., Kalimuddin, S., Young, B.E., Runnegar, N., Andresen, D.N., Anagnostou, N.A., Johnson, S.A., Chatfield, M.D., Cheng, A.C., Fowler, V.G., Howden, B.P., Meagher, N., Price, D.J., van Hal, S.J., O’Sullivan, M.V. N., and Davis, J.S.
- Abstract
Importance Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%. Combining standard therapy with a β-lactam antibiotic has been associated with reduced mortality, although adequately powered randomized clinical trials of this intervention have not been conducted. Objective To determine whether combining an antistaphylococcal β-lactam with standard therapy is more effective than standard therapy alone in patients with MRSA bacteremia. Design, Setting, and Participants Open-label, randomized clinical trial conducted at 27 hospital sites in 4 countries from August 2015 to July 2018 among 352 hospitalized adults with MRSA bacteremia. Follow-up was complete on October 23, 2018. Interventions Participants were randomized to standard therapy (intravenous vancomycin or daptomycin) plus an antistaphylococcal β-lactam (intravenous flucloxacillin, cloxacillin, or cefazolin) (n = 174) or standard therapy alone (n = 178). Total duration of therapy was determined by treating clinicians and the β-lactam was administered for 7 days. Main Outcomes and Measures The primary end point was a 90-day composite of mortality, persistent bacteremia at day 5, microbiological relapse, and microbiological treatment failure. Secondary outcomes included mortality at days 14, 42, and 90; persistent bacteremia at days 2 and 5; acute kidney injury (AKI); microbiological relapse; microbiological treatment failure; and duration of intravenous antibiotics. Results The data and safety monitoring board recommended early termination of the study prior to enrollment of 440 patients because of safety. Among 352 patients randomized (mean age, 62.2 [SD, 17.7] years; 121 women [34.4%]), 345 (98%) completed the trial. The primary end point was met by 59 (35%) with combination therapy and 68 (39%) with standard therapy (absolute difference, −4.2%; 95% CI, −14.3% to 6.0%). Seven of 9 prespecified secondary end points showed no significant difference. For the
- Published
- 2020
14. Vancomycin exposure and acute kidney injury outcome: A Snapshot From the CAMERA2 Study
- Author
-
Liu, J., Tong, S.Y.C., Davis, J.S., Rhodes, N.J., Scheetz, M.H., Anagostou, N., Andresen, D., Archuleta, S., Bak, N., Cass, A., Chatfield, M., Cheng, A., Davies, J., Davis, J., Dishon, Y., Dotel, R., Ferguson, P., Foo, H., Fowler, V., Ghosh, N., Gray, T., Guy, S., Holmes, N., Howden, B., Johnson, S., Kalimuddin, S., Lye, D., McBride, S., McKew, G., Meagher, N., Nelson, J., O’Sullivan, M., Paterson, D., Paul, M., Price, D., Ralph, A., Roberts, M., Robinson, O., Rogers, B., Runnegar, N., Smith, S., Sud, A., Tong, S., Tramontana, A., Van Hal, S., Walls, G., Warner, M., Yahav, D., Young, B., Liu, J., Tong, S.Y.C., Davis, J.S., Rhodes, N.J., Scheetz, M.H., Anagostou, N., Andresen, D., Archuleta, S., Bak, N., Cass, A., Chatfield, M., Cheng, A., Davies, J., Davis, J., Dishon, Y., Dotel, R., Ferguson, P., Foo, H., Fowler, V., Ghosh, N., Gray, T., Guy, S., Holmes, N., Howden, B., Johnson, S., Kalimuddin, S., Lye, D., McBride, S., McKew, G., Meagher, N., Nelson, J., O’Sullivan, M., Paterson, D., Paul, M., Price, D., Ralph, A., Roberts, M., Robinson, O., Rogers, B., Runnegar, N., Smith, S., Sud, A., Tong, S., Tramontana, A., Van Hal, S., Walls, G., Warner, M., Yahav, D., and Young, B.
- Abstract
Among patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia from a prospective randomized clinical trial, acute kidney injury (AKI) rates increased with increasing vancomycin exposure, even within the therapeutic range. AKI was independently more common for the (flu)cloxacillin group. Day 2 vancomycin AUC ≥470 mg·h/L was significantly associated with AKI, independent of (flu)cloxacillin receipt.
- Published
- 2020
15. Effect of Vancomycin or Daptomycin with vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients with MRSA Bacteremia: A Randomized Clinical Trial.
- Author
-
Tramontana A.R., Tong S.Y.C., Lye D.C., Yahav D., Sud A., Robinson J.O., Nelson J., Archuleta S., Roberts M.A., Cass A., Paterson D.L., Foo H., Paul M., Guy S.D., Runnegar N., Andresen D.N., Anagnostou N.A., Johnson S.A., Chatfield M.D., Cheng A.C., Fowler V.G., Howden B.P., Meagher N., Price D.J., Van Hal S.J., O'Sullivan M.V.N., Davis J.S., Walls G.B., McBride S., Bak N., Ghosh N., Rogers B.A., Ralph A.P., Davies J., Ferguson P.E., Dotel R., McKew G.L., Gray T.J., Holmes N.E., Smith S., Warner M.S., Kalimuddin S., Young B.E., Tramontana A.R., Tong S.Y.C., Lye D.C., Yahav D., Sud A., Robinson J.O., Nelson J., Archuleta S., Roberts M.A., Cass A., Paterson D.L., Foo H., Paul M., Guy S.D., Runnegar N., Andresen D.N., Anagnostou N.A., Johnson S.A., Chatfield M.D., Cheng A.C., Fowler V.G., Howden B.P., Meagher N., Price D.J., Van Hal S.J., O'Sullivan M.V.N., Davis J.S., Walls G.B., McBride S., Bak N., Ghosh N., Rogers B.A., Ralph A.P., Davies J., Ferguson P.E., Dotel R., McKew G.L., Gray T.J., Holmes N.E., Smith S., Warner M.S., Kalimuddin S., and Young B.E.
- Abstract
Importance: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%. Combining standard therapy with a beta-lactam antibiotic has been associated with reduced mortality, although adequately powered randomized clinical trials of this intervention have not been conducted. Objective(s): To determine whether combining an antistaphylococcal beta-lactam with standard therapy is more effective than standard therapy alone in patients with MRSA bacteremia. Design, Setting, and Participant(s): Open-label, randomized clinical trial conducted at 27 hospital sites in 4 countries from August 2015 to July 2018 among 352 hospitalized adults with MRSA bacteremia. Follow-up was complete on October 23, 2018. Intervention(s): Participants were randomized to standard therapy (intravenous vancomycin or daptomycin) plus an antistaphylococcal beta-lactam (intravenous flucloxacillin, cloxacillin, or cefazolin) (n = 174) or standard therapy alone (n = 178). Total duration of therapy was determined by treating clinicians and the beta-lactam was administered for 7 days. Main Outcomes and Measures: The primary end point was a 90-day composite of mortality, persistent bacteremia at day 5, microbiological relapse, and microbiological treatment failure. Secondary outcomes included mortality at days 14, 42, and 90; persistent bacteremia at days 2 and 5; acute kidney injury (AKI); microbiological relapse; microbiological treatment failure; and duration of intravenous antibiotics. Result(s): The data and safety monitoring board recommended early termination of the study prior to enrollment of 440 patients because of safety. Among 352 patients randomized (mean age, 62.2 [SD, 17.7] years; 121 women [34.4%]), 345 (98%) completed the trial. The primary end point was met by 59 (35%) with combination therapy and 68 (39%) with standard therapy (absolute difference, -4.2%; 95% CI, -14.3% to 6.0%). Seven of 9 prespecified secondary end points showed no signi
- Published
- 2020
16. A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naive schizophrenia patients based on multimodal neuropsychiatric data
- Author
-
Ambrosen, KS, Skjerbaek, MW, Foldager, J, Axelsen, MC, Bak, N, Arvastson, L, Christensen, SR, Johansen, LB, Raghava, JM, Oranje, B, Rostrup, E, Nielsen, MO, Osler, M, Fagerlund, B, Pantelis, C, Kinon, BJ, Glenthoj, BY, Hansen, LK, Ebdrup, BH, Ambrosen, KS, Skjerbaek, MW, Foldager, J, Axelsen, MC, Bak, N, Arvastson, L, Christensen, SR, Johansen, LB, Raghava, JM, Oranje, B, Rostrup, E, Nielsen, MO, Osler, M, Fagerlund, B, Pantelis, C, Kinon, BJ, Glenthoj, BY, Hansen, LK, and Ebdrup, BH
- Abstract
The reproducibility of machine-learning analyses in computational psychiatry is a growing concern. In a multimodal neuropsychiatric dataset of antipsychotic-naïve, first-episode schizophrenia patients, we discuss a workflow aimed at reducing bias and overfitting by invoking simulated data in the design process and analysis in two independent machine-learning approaches, one based on a single algorithm and the other incorporating an ensemble of algorithms. We aimed to (1) classify patients from controls to establish the framework, (2) predict short- and long-term treatment response, and (3) validate the methodological framework. We included 138 antipsychotic-naïve, first-episode schizophrenia patients with data on psychopathology, cognition, electrophysiology, and structural magnetic resonance imaging (MRI). Perinatal data and long-term outcome measures were obtained from Danish registers. Short-term treatment response was defined as change in Positive And Negative Syndrome Score (PANSS) after the initial antipsychotic treatment period. Baseline diagnostic classification algorithms also included data from 151 matched controls. Both approaches significantly classified patients from healthy controls with a balanced accuracy of 63.8% and 64.2%, respectively. Post-hoc analyses showed that the classification primarily was driven by the cognitive data. Neither approach predicted short- nor long-term treatment response. Validation of the framework showed that choice of algorithm and parameter settings in the real data was successfully guided by results from the simulated data. In conclusion, this novel approach holds promise as an important step to minimize bias and obtain reliable results with modest sample sizes when independent replication samples are not available.
- Published
- 2020
17. S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
- Author
-
Ambrosen, KS, Skjerbæk, MW, Foldager, J, Axelsen, MC, Bak, N, Arvastson, L, Christensen, SR, Johansen, LB, Raghava, JM, Oranje, B, Rostrup, E, Nielsen, MØ, Osler, M, Fagerlund, B, Pantelis, C, Kinon, BJ, Glenthøj, BY, Hansen, LK, Ebdrup, BH, Ambrosen, KS, Skjerbæk, MW, Foldager, J, Axelsen, MC, Bak, N, Arvastson, L, Christensen, SR, Johansen, LB, Raghava, JM, Oranje, B, Rostrup, E, Nielsen, MØ, Osler, M, Fagerlund, B, Pantelis, C, Kinon, BJ, Glenthøj, BY, Hansen, LK, and Ebdrup, BH
- Published
- 2020
18. Risk factors for candidaemia: A prospective multi-centre case-control study
- Author
-
Keighley, CL, Pope, A, Marriott, DJE, Chapman, B, Bak, N, Daveson, K, Hajkowicz, K, Halliday, C, Kennedy, K, Kidd, S, Sorrell, TC, Underwood, N, van Hal, S, Slavin, MA, Chen, SC-A, Keighley, CL, Pope, A, Marriott, DJE, Chapman, B, Bak, N, Daveson, K, Hajkowicz, K, Halliday, C, Kennedy, K, Kidd, S, Sorrell, TC, Underwood, N, van Hal, S, Slavin, MA, and Chen, SC-A
- Abstract
OBJECTIVES: Candidaemia carries a mortality of up to 40% and may be related to increasing complexity of medical care. Here, we determined risk factors for the development of candidaemia. METHODS: We conducted a prospective, multi-centre, case-control study over 12 months. Cases were aged ≥18 years with at least one blood culture positive for Candida spp. Each case was matched with two controls, by age within 10 years, admission within 6 months, admitting unit, and admission duration at least as long as the time between admission and onset of candidaemia. RESULTS: A total of 118 incident cases and 236 matched controls were compared. By multivariate analysis, risk factors for candidaemia included neutropenia, solid organ transplant, significant liver, respiratory or cardiovascular disease, recent gastrointestinal, biliary or urological surgery, central venous access device, intravenous drug use, urinary catheter and carbapenem receipt. CONCLUSIONS: Risk factors for candidaemia derive from the infection source, carbapenem use, host immune function and organ-based co-morbidities. Preventive strategies should target iatrogenic disruption of mucocutaneous barriers and intravenous drug use.
- Published
- 2020
19. Cryptococcus gattii infection: Long term morbidity and determinants of neurological sequelae and death: C6-1
- Author
-
Chen, S., Slavin, M., Heath, C., Playford, E. G., Byth, K., Marriott, D., Kidd, S., Bak, N., Currie, B., Hajkowicz, K., Korman, T., McBride, W. J., Meyer, W., Murray, R., and Sorrell, T.
- Published
- 2012
20. The impact of schizophrenia and intelligence on the relationship between age and brain volume
- Author
-
Jensen, MH, Bak, N, Rostrup, E, Nielsen, MO, Pantelis, C, Glenthoj, BY, Ebdrup, BH, Fagerlund, B, Jensen, MH, Bak, N, Rostrup, E, Nielsen, MO, Pantelis, C, Glenthoj, BY, Ebdrup, BH, and Fagerlund, B
- Abstract
Age has been shown to have an impact on both grey (GM) and white matter (WM) volume, with a steeper slope of age-related decline in schizophrenia compared to healthy controls. In schizophrenia, the relation between age and brain volume is further complicated by factors such as lower intelligence, antipsychotic medication, and cannabis use, all of which have been shown to have independent effects on brain volume. In a study of first-episode, antipsychotic-naïve schizophrenia patients (N = 54) and healthy controls (N = 56), we examined the effects of age on whole brain measures of GM and WM volume, and whether these relationships were moderated by schizophrenia and intelligence (IQ). Secondarily, we examined lifetime cannabis use as a moderator of the relationship between age and brain volume. Schizophrenia patients had lower GM volumes than healthy controls but did not differ on WM volume. We found an age effect on GM indicating that increasing age was associated with lower GM volumes, which did not differ between groups. IQ did not have a direct effect on GM, but showed a trend-level interaction with age, suggesting a greater impact of age with lower IQ. There were no age effects on WM volume, but a direct effect of IQ, with higher IQ showing an association with larger WM volume. Lifetime cannabis use did not alter these findings significantly. This study points to effects of schizophrenia on GM early in the illness, before antipsychotic treatment is initiated, suggesting that WM changes may occur later in the disease process.
- Published
- 2019
21. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement
- Author
-
Doyle, J, Raggatt, M, Slavin, M, McLachlan, S-A, Strasser, SI, Sasadeusz, JJ, Howell, J, Hajkowicz, K, Nandurkar, H, Johnston, A, Bak, N, Thompson, AJ, Doyle, J, Raggatt, M, Slavin, M, McLachlan, S-A, Strasser, SI, Sasadeusz, JJ, Howell, J, Hajkowicz, K, Nandurkar, H, Johnston, A, Bak, N, and Thompson, AJ
- Abstract
INTRODUCTION: Individuals with chronic hepatitis B virus (HBV) infection or past exposure to HBV infection have a substantial risk of reactivation during immunosuppressive cancer therapy. HBV reactivation can lead to liver failure, cancer treatment interruption or death. Clinical concordance with screening and treatment guidelines is inconsistent in practice, and existing international guidelines are not specific to the Australian context. We developed an Australian consensus statement with infectious diseases, hepatology, haematology and oncology specialists to inform hepatitis B screening and antiviral management for immunocompromised patients with haematological and solid organ malignancies in Australia. MAIN RECOMMENDATIONS: Recommendations address four key areas of HBV infection management for immunocompromised patients with haematological and solid organ malignancies: who to test for HBV infection, when to start antiviral agents, when to stop antiviral agents, and how to monitor patients during cancer therapy. We recommend testing all patients undergoing cancer treatment for hepatitis B (including HBV surface antigen [HBsAg], HBV core antibody [anti-HBc], and HBV surface antibody) before cancer treatment. Individuals with chronic HBV infection (HBsAg positive) or past exposure (HBsAg negative and anti-HBc positive) receiving higher risk chemotherapy require antiviral prophylaxis using entecavir or tenofovir. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This consensus statement will simplify the approach to testing and prophylaxis for HBV infection during cancer therapy, and harmonise approaches to discontinuing and monitoring individuals which have been highly variable in practice. We advocate for broader Medicare Benefits Schedule and Pharmaceutical Benefits Scheme access to HBV testing and treatment for patients undergoing cancer therapy.
- Published
- 2019
22. Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study
- Author
-
Keighley, C, Chen, SC-A, Marriott, D, Pope, A, Chapman, B, Kennedy, K, Bak, N, Underwood, N, Wilson, HL, McDonald, K, Darvall, J, Halliday, C, Kidd, S, Nguyen, Q, Hajkowicz, K, Sorrell, TC, Van Hal, S, Slavin, MA, Keighley, C, Chen, SC-A, Marriott, D, Pope, A, Chapman, B, Kennedy, K, Bak, N, Underwood, N, Wilson, HL, McDonald, K, Darvall, J, Halliday, C, Kidd, S, Nguyen, Q, Hajkowicz, K, Sorrell, TC, Van Hal, S, and Slavin, MA
- Abstract
BACKGROUND: Candidaemia is associated with high mortality. Variables associated with mortality have been published previously, but not developed into a risk predictive model for mortality. We sought to describe the current epidemiology of candidaemia in Australia, analyse predictors of 30-day all-cause mortality, and develop and validate a mortality risk predictive model. METHODS: Adults with candidaemia were studied prospectively over 12 months at eight institutions. Clinical and laboratory variables at time of blood culture-positivity were subject to multivariate analysis for association with 30-day all-cause mortality. A predictive score for mortality was examined by area under receiver operator characteristic curves and a historical data set was used for validation. RESULTS: The median age of 133 patients with candidaemia was 62 years; 76 (57%) were male and 57 (43%) were female. Co-morbidities included underlying haematologic malignancy (n = 20; 15%), and solid organ malignancy in (n = 25; 19%); 55 (41%) were in an intensive care unit (ICU). Non-albicans Candida spp. accounted for 61% of cases (81/133). All-cause 30-day mortality was 31%. A gastrointestinal or unknown source was associated with higher overall mortality than an intravascular or urologic source (p < 0.01). A risk predictive score based on age > 65 years, ICU admission, chronic organ dysfunction, preceding surgery within 30 days, haematological malignancy, source of candidaemia and antibiotic therapy for ≥10 days stratified patients into < 20% or ≥ 20% predicted mortality. The model retained accuracy when validated against a historical dataset (n = 741). CONCLUSIONS: Mortality in patients with candidaemia remains high. A simple mortality risk predictive score stratifying patients with candidaemia into < 20% and ≥ 20% 30-day mortality is presented. This model uses information available at time of candidaemia diagnosis is easy to incorporate into decision support systems. Further validation of this
- Published
- 2019
23. Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method
- Author
-
Randau, M., Oranje, B., Miyakoshi, M., Makeig, S., Fagerlund, Birgitte, Glenthøj, B., Bak, N., Randau, M., Oranje, B., Miyakoshi, M., Makeig, S., Fagerlund, Birgitte, Glenthøj, B., and Bak, N.
- Abstract
Background: Mismatch negativity (MMN) is a measure of pre-attentive auditory information processing related to change detection. Traditional scalp-level EEG methods consistently find attenuated MMN in patients with chronic but not first-episode schizophrenia. In the current paper, we use a source-resolved method to assess MMN and hypothesize that more subtle changes can be identified with this analysis method. Method: Fifty-six first-episode antipsychotic-naïve schizophrenia (FEANS) patients (31 males, 25 females, mean age 24.6) and 64 matched controls (37 males, 27 females, mean age 24.8) were assessed for duration-, frequency- and combined-type MMN and P3a as well as 4 clinical, 3 cognitive and 3 psychopathological measures. To evaluate and correlate MMN at source-level, independent component analysis (ICA) was applied to the continuous EEG data to derive equivalent current dipoles which were clustered into 19 clusters based on cortical location. Results: No scalp channel group MMN or P3a amplitude differences were found. Of the localized clusters, several were in or near brain areas previously suggested to be involved in the MMN response, including frontal and anterior cingulate cortices and superior temporal and inferior frontal gyri. For duration deviants, MMN was attenuated at the right superior temporal gyrus in patients compared to healthy controls (p = 0.01), as was P3a at the superior frontal cortex (p = 0.01). No individual patient correlations with clinical, cognitive, or psychopathological measures survived correction for multiple comparisons. Conclusion: Attenuated source-localized MMN and P3a peak contributions can be identified in FEANS patients using a method based on independent component analysis (ICA). This indicates that deficits in pre-attentive auditory information processing are present at this early stage of schizophrenia and are not the result of disease chronicity or medication. This is to our knowledge the first study on FEANS patients
- Published
- 2019
24. Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method
- Author
-
Randau, M., primary, Oranje, B., additional, Miyakoshi, M., additional, Makeig, S., additional, Fagerlund, B., additional, Glenthøj, B., additional, and Bak, N., additional
- Published
- 2019
- Full Text
- View/download PDF
25. Vancomycin-resistant Enterococcus faecium sequence type 796 - rapid international dissemination of a new epidemic clone.
- Author
-
Stuart R.L., Kotsanas D., Cheng A., Heffernan H., Roberts S.A., Ferguson J.K., Carter G.C., Howden B.P., Stinear T.P., Johnson P.D.R., Mahony A.A., Buultjens A.H., Ballard S.A., Grabsch E.A., Xie S., Seemann T., Coombs G.W., Bak N., Stuart R.L., Kotsanas D., Cheng A., Heffernan H., Roberts S.A., Ferguson J.K., Carter G.C., Howden B.P., Stinear T.P., Johnson P.D.R., Mahony A.A., Buultjens A.H., Ballard S.A., Grabsch E.A., Xie S., Seemann T., Coombs G.W., and Bak N.
- Abstract
Background: Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired infections. New, presumably better-adapted strains of VRE appear unpredictably; it is uncertain how they spread despite improved infection control. We aimed to investigate the relatedness of a novel sequence type (ST) of vanB E. faecium - ST796 - very near its time of origin from hospitals in three Australian states and New Zealand. Method(s): Following near-simultaneous outbreaks of ST796 in multiple institutions, we gathered then tested colonization and bloodstream infection isolates' antimicrobial resistance (AMR) phenotypes, and phylogenomic relationships using whole genome sequencing (WGS). Patient meta-data was explored to trace the spread of ST796. Result(s): A novel clone of vanB E. faecium (ST796) was first detected at one Australian hospital in late 2011, then in two New Zealand hospitals linked by inter-hospital transfers from separate Melbourne hospitals. ST796 also appeared in hospitals in South Australia and New South Wales and was responsible for at least one major colonization outbreak in a Neonatal Intensive Care Unit without identifiable links between centers. No exceptional AMR was detected in the isolates. While WGS analysis showed very limited diversity at the core genome, consistent with recent emergence of the clone, clustering by institution was observed. Conclusion(s): Evolution of new E. faecium clones, followed by recognized or unrecognized movement of colonized individuals then rapid intra-institutional cross-transmission best explain the multi-center, multistate and international outbreak we observed.Copyright © 2018 The Author(s).
- Published
- 2018
26. Vancomycin-resistant Enterococcus faecium sequence type 796 - rapid international dissemination of a new epidemic clone
- Author
-
Mahony, A.A., Buultjens, A.H., Ballard, S.A., Grabsch, E.A., Xie, S., Seemann, T., Stuart, R.L., Kotsanas, D., Cheng, A., Heffernan, H., Roberts, S.A., Coombs, G.W., Bak, N., Ferguson, J.K., Carter, G.C., Howden, B.P., Stinear, T.P., Johnson, P.D.R., Mahony, A.A., Buultjens, A.H., Ballard, S.A., Grabsch, E.A., Xie, S., Seemann, T., Stuart, R.L., Kotsanas, D., Cheng, A., Heffernan, H., Roberts, S.A., Coombs, G.W., Bak, N., Ferguson, J.K., Carter, G.C., Howden, B.P., Stinear, T.P., and Johnson, P.D.R.
- Abstract
Background: Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired infections. New, presumably better-adapted strains of VRE appear unpredictably; it is uncertain how they spread despite improved infection control. We aimed to investigate the relatedness of a novel sequence type (ST) of vanB E. faecium - ST796 - very near its time of origin from hospitals in three Australian states and New Zealand. Methods: Following near-simultaneous outbreaks of ST796 in multiple institutions, we gathered then tested colonization and bloodstream infection isolates' antimicrobial resistance (AMR) phenotypes, and phylogenomic relationships using whole genome sequencing (WGS). Patient meta-data was explored to trace the spread of ST796. Results: A novel clone of vanB E. faecium (ST796) was first detected at one Australian hospital in late 2011, then in two New Zealand hospitals linked by inter-hospital transfers from separate Melbourne hospitals. ST796 also appeared in hospitals in South Australia and New South Wales and was responsible for at least one major colonization outbreak in a Neonatal Intensive Care Unit without identifiable links between centers. No exceptional AMR was detected in the isolates. While WGS analysis showed very limited diversity at the core genome, consistent with recent emergence of the clone, clustering by institution was observed. Conclusions: Evolution of new E. faecium clones, followed by recognized or unrecognized movement of colonized individuals then rapid intra-institutional cross-transmission best explain the multi-center, multistate and international outbreak we observed.
- Published
- 2018
27. Vancomycin-resistant Enterococcus faecium sequence type 796-rapid international dissemination of a new epidemic clone
- Author
-
Mahony, AA, Buultjens, AH, Ballard, SA, Grabsch, EA, Xie, S, Seemann, T, Stuart, RL, Kotsanas, D, Cheng, A, Heffernan, H, Roberts, SA, Coombs, GW, Bak, N, Ferguson, JK, Carter, GC, Howden, BP, Stinear, TP, Johnson, PDR, Mahony, AA, Buultjens, AH, Ballard, SA, Grabsch, EA, Xie, S, Seemann, T, Stuart, RL, Kotsanas, D, Cheng, A, Heffernan, H, Roberts, SA, Coombs, GW, Bak, N, Ferguson, JK, Carter, GC, Howden, BP, Stinear, TP, and Johnson, PDR
- Abstract
BACKGROUND: Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired infections. New, presumably better-adapted strains of VRE appear unpredictably; it is uncertain how they spread despite improved infection control. We aimed to investigate the relatedness of a novel sequence type (ST) of vanB E. faecium - ST796 - very near its time of origin from hospitals in three Australian states and New Zealand. METHODS: Following near-simultaneous outbreaks of ST796 in multiple institutions, we gathered then tested colonization and bloodstream infection isolates' antimicrobial resistance (AMR) phenotypes, and phylogenomic relationships using whole genome sequencing (WGS). Patient meta-data was explored to trace the spread of ST796. RESULTS: A novel clone of vanB E. faecium (ST796) was first detected at one Australian hospital in late 2011, then in two New Zealand hospitals linked by inter-hospital transfers from separate Melbourne hospitals. ST796 also appeared in hospitals in South Australia and New South Wales and was responsible for at least one major colonization outbreak in a Neonatal Intensive Care Unit without identifiable links between centers. No exceptional AMR was detected in the isolates. While WGS analysis showed very limited diversity at the core genome, consistent with recent emergence of the clone, clustering by institution was observed. CONCLUSIONS: Evolution of new E. faecium clones, followed by recognized or unrecognized movement of colonized individuals then rapid intra-institutional cross-transmission best explain the multi-center, multistate and international outbreak we observed.
- Published
- 2018
28. Vancomycin-resistant Enterococcus faecium sequence type 796 - rapid international dissemination of a new epidemic clone
- Author
-
Mahony, A., Buultjens, A., Ballard, S., Grabsch, E., Xie, S., Seemann, T., Stuart, R., Kotsanas, D., Cheng, A., Heffernan, H., Roberts, S., Coombs, Geoffrey, Bak, N., Ferguson, J., Carter, G., Howden, B., Stinear, T., Johnson, P., Mahony, A., Buultjens, A., Ballard, S., Grabsch, E., Xie, S., Seemann, T., Stuart, R., Kotsanas, D., Cheng, A., Heffernan, H., Roberts, S., Coombs, Geoffrey, Bak, N., Ferguson, J., Carter, G., Howden, B., Stinear, T., and Johnson, P.
- Abstract
Background: Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired infections. New, presumably better-adapted strains of VRE appear unpredictably; it is uncertain how they spread despite improved infection control. We aimed to investigate the relatedness of a novel sequence type (ST) of vanB E. faecium - ST796 - very near its time of origin from hospitals in three Australian states and New Zealand. Methods: Following near-simultaneous outbreaks of ST796 in multiple institutions, we gathered then tested colonization and bloodstream infection isolates' antimicrobial resistance (AMR) phenotypes, and phylogenomic relationships using whole genome sequencing (WGS). Patient meta-data was explored to trace the spread of ST796. Results: A novel clone of vanB E. faecium (ST796) was first detected at one Australian hospital in late 2011, then in two New Zealand hospitals linked by inter-hospital transfers from separate Melbourne hospitals. ST796 also appeared in hospitals in South Australia and New South Wales and was responsible for at least one major colonization outbreak in a Neonatal Intensive Care Unit without identifiable links between centers. No exceptional AMR was detected in the isolates. While WGS analysis showed very limited diversity at the core genome, consistent with recent emergence of the clone, clustering by institution was observed. Conclusions: Evolution of new E. faecium clones, followed by recognized or unrecognized movement of colonized individuals then rapid intra-institutional cross-transmission best explain the multi-center, multistate and international outbreak we observed.
- Published
- 2018
29. Changing epidemiology of candidaemia in Australia.
- Author
-
Goeman E., Robson J., Korman T.M., Pendle S., Weeks K., Liu E., Cheong E., Chen S., Daveson K., Wilson H., Thomas M., Peachey G., Gottlieb T., Lui E., Jozwiak F., Bell S.M., Kotsiou G., Chen S.C.-A., Marshall C., Ferguson C., Bryant M., Reed C., Darvall J., Maddigan V., Boan P., Menon V., Chapman B., Slavin M., Marriott D., Halliday C., Kidd S.E., Arthur I., Bak N., Heath C., Kennedy K., Morrissey C.O., Sorrell T., van Hal S., Keighley C., Underwood N., Hajkowicz K., Hofmeyr A., Leung M., Macesic N., Botes J., Blyth C., Cooley L., George C.R., Kalukottege R.P., Kesson A., McMullan B., Baird R., Goeman E., Robson J., Korman T.M., Pendle S., Weeks K., Liu E., Cheong E., Chen S., Daveson K., Wilson H., Thomas M., Peachey G., Gottlieb T., Lui E., Jozwiak F., Bell S.M., Kotsiou G., Chen S.C.-A., Marshall C., Ferguson C., Bryant M., Reed C., Darvall J., Maddigan V., Boan P., Menon V., Chapman B., Slavin M., Marriott D., Halliday C., Kidd S.E., Arthur I., Bak N., Heath C., Kennedy K., Morrissey C.O., Sorrell T., van Hal S., Keighley C., Underwood N., Hajkowicz K., Hofmeyr A., Leung M., Macesic N., Botes J., Blyth C., Cooley L., George C.R., Kalukottege R.P., Kesson A., McMullan B., and Baird R.
- Abstract
Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Method(s): These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Result(s): A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusion(s):We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.Copyright © The Author 2016.
- Published
- 2017
30. Erratum: Changing epidemiology of candidaemia in Australia [J Antimicrob Chemother, 72, (2017) (1103-1108)] DOI:10.1093/jac/dkw422.
- Author
-
Baird R., Cooley L., George C.R., Kalukottege P., Kesson A., McMullan B., Robson J., Chen S., Cheong E., Liu E., Weeks K., Pendle S., Korman T.M., Chapman B., Slavin M., Marriott D., Halliday C., Kidd S., Arthur I., Bak N., Heath C.H., Kennedy K., Morrissey C.O., Sorrell T.C., van Hal S., Keighley C., Goeman E., Underwood N., Hajkowicz K., Hofmeyr A., Leung M., Macesic N., Botes J., Blyth C., Baird R., Cooley L., George C.R., Kalukottege P., Kesson A., McMullan B., Robson J., Chen S., Cheong E., Liu E., Weeks K., Pendle S., Korman T.M., Chapman B., Slavin M., Marriott D., Halliday C., Kidd S., Arthur I., Bak N., Heath C.H., Kennedy K., Morrissey C.O., Sorrell T.C., van Hal S., Keighley C., Goeman E., Underwood N., Hajkowicz K., Hofmeyr A., Leung M., Macesic N., Botes J., and Blyth C.
- Abstract
In the original published version of this article two authors (Eunice Liu and Elaine Cheong) were inadvertently omitted from the author list during article preparation. This error has now been corrected. The authors apologize for this error.Copyright © The Author 2016.
- Published
- 2017
31. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology
- Author
-
Bak, N, Ebdrup, B H, Oranje, B, Fagerlund, B, Jensen, M H, Düring, S W, Nielsen, M Ø, Glenthøj, B Y, Hansen, L K, Bak, N, Ebdrup, B H, Oranje, B, Fagerlund, B, Jensen, M H, Düring, S W, Nielsen, M Ø, Glenthøj, B Y, and Hansen, L K
- Abstract
Deficits in information processing and cognition are among the most robust findings in schizophrenia patients. Previous efforts to translate group-level deficits into clinically relevant and individualized information have, however, been non-successful, which is possibly explained by biologically different disease subgroups. We applied machine learning algorithms on measures of electrophysiology and cognition to identify potential subgroups of schizophrenia. Next, we explored subgroup differences regarding treatment response. Sixty-six antipsychotic-naive first-episode schizophrenia patients and sixty-five healthy controls underwent extensive electrophysiological and neurocognitive test batteries. Patients were assessed on the Positive and Negative Syndrome Scale (PANSS) before and after 6 weeks of monotherapy with the relatively selective D2 receptor antagonist, amisulpride (280.3±159 mg per day). A reduced principal component space based on 19 electrophysiological variables and 26 cognitive variables was used as input for a Gaussian mixture model to identify subgroups of patients. With support vector machines, we explored the relation between PANSS subscores and the identified subgroups. We identified two statistically distinct subgroups of patients. We found no significant baseline psychopathological differences between these subgroups, but the effect of treatment in the groups was predicted with an accuracy of 74.3% (P=0.003). In conclusion, electrophysiology and cognition data may be used to classify subgroups of schizophrenia patients. The two distinct subgroups, which we identified, were psychopathologically inseparable before treatment, yet their response to dopaminergic blockade was predicted with significant accuracy. This proof of principle encourages further endeavors to apply data-driven, multivariate and multimodal models to facilitate progress from symptom-based psychiatry toward individualized treatment regimens.
- Published
- 2017
32. Testing a decades' old assumption:Are individuals with lower sensory gating indeed more easily distracted?
- Author
-
Bak, N, Mann, J, Fagerlund, B, Glenthøj, B Y, Jepsen, J R M, Oranje, B, Bak, N, Mann, J, Fagerlund, B, Glenthøj, B Y, Jepsen, J R M, and Oranje, B
- Abstract
The sensory gating deficits in schizophrenia have been theorized to associate with increased distractibility. We explore the potential associations between sensory and sensorimotor gating and subjective and objective indices of distraction in healthy subjects. Forty healthy males were assessed with the P50 suppression and pre-pulse inhibition of the startle reflex (PPI) paradigms. Additionally, a neurocognitive test battery was administered in a cross-over design: with/without auditory distraction. Significant effects of distraction were found in response inhibition, and verbal working memory and attention. Parameters from the PPI and P50 suppression paradigms were significantly associated with the distractor effects on strategy formation, cognitive inhibition and flexibility, visual short-term memory, and the level of subjective distraction. Subjectively reported distraction was significantly associated with verbal working memory and attention as well as executive and supervisory processes. Sensory and sensorimotor gating efficiency do not reflect the effect of distraction across executive and attention functions i.e. we did not observe a generalized distractor effect. Gating only related to the effect of distraction on strategy formation, cognitive inhibition and flexibility, as well as visual short term memory. Future studies should investigate if gating deficits affect the distractibility of the same specific cognitive functions in patients with schizophrenia.
- Published
- 2017
33. 'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia':authors' response
- Author
-
Ebdrup, B H, Ishøy, P L, Fagerlund, B, Broberg, B V, Bak, N, Knop, F K, Glenthøj, B Y, Ebdrup, B H, Ishøy, P L, Fagerlund, B, Broberg, B V, Bak, N, Knop, F K, and Glenthøj, B Y
- Published
- 2017
34. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia
- Author
-
Ishøy, P L, Fagerlund, B, Broberg, B V, Bak, N, Knop, F K, Glenthøj, B Y, Ebdrup, B H, Ishøy, P L, Fagerlund, B, Broberg, B V, Bak, N, Knop, F K, Glenthøj, B Y, and Ebdrup, B H
- Abstract
OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder.METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS). We used BACS composite score as the main outcome measure.RESULTS: Repeated measures analysis of variance on BACS composite score showed significant effect of 'Time' (P < 0.001), no effect of 'Group' (P = 0.64) and no 'Time*Group' interaction (P = 0.77). For REY, SF-36, PSP and PANSS, only significant 'Time' effects were found.CONCLUSION: The non-significant results of this first clinical trial exploring non-metabolic effects of a long-acting GLP-1RA in patients with schizophrenia could reflect a general problem of translating cognitive-enhancing effects of GLP-1RAs from animals to humans or be explained by factors specifically related to schizophrenia spectrum patients with obesity such as antipsychotic treatment.
- Published
- 2017
35. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology
- Author
-
Bak, N., Ebdrup, B.H., Oranje, B, Fagerlund, B, Jensen, M H, Düring, S W, Nielsen, M Ø, Glenthøj, Birte Y., Hansen, Lars Kai, Bak, N., Ebdrup, B.H., Oranje, B, Fagerlund, B, Jensen, M H, Düring, S W, Nielsen, M Ø, Glenthøj, Birte Y., and Hansen, Lars Kai
- Abstract
Deficits in information processing and cognition are among the most robust findings in schizophrenia patients. Previous efforts to translate group-level deficits into clinically relevant and individualized information have, however, been non-successful, which is possibly explained by biologically different disease subgroups. We applied machine learning algorithms on measures of electrophysiology and cognition to identify potential subgroups of schizophrenia. Next, we explored subgroup differences regarding treatment response. Sixty-six antipsychotic-naive first-episode schizophrenia patients and sixty-five healthy controls underwent extensive electrophysiological and neurocognitive test batteries. Patients were assessed on the Positive and Negative Syndrome Scale (PANSS) before and after 6 weeks of monotherapy with the relatively selective D2 receptor antagonist, amisulpride (280.3±159 mg per day). A reduced principal component space based on 19 electrophysiological variables and 26 cognitive variables was used as input for a Gaussian mixture model to identify subgroups of patients. With support vector machines, we explored the relation between PANSS subscores and the identified subgroups. We identified two statistically distinct subgroups of patients. We found no significant baseline psychopathological differences between these subgroups, but the effect of treatment in the groups was predicted with an accuracy of 74.3% (P=0.003). In conclusion, electrophysiology and cognition data may be used to classify subgroups of schizophrenia patients. The two distinct subgroups, which we identified, were psychopathologically inseparable before treatment, yet their response to dopaminergic blockade was predicted with significant accuracy. This proof of principle encourages further endeavors to apply data-driven, multivariate and multimodal models to facilitate progress from symptom-based psychiatry toward individualized treatment regimens.
- Published
- 2017
36. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology
- Author
-
Bak, N, primary, Ebdrup, B H, additional, Oranje, B, additional, Fagerlund, B, additional, Jensen, M H, additional, Düring, S W, additional, Nielsen, M Ø, additional, Glenthøj, B Y, additional, and Hansen, L K, additional
- Published
- 2017
- Full Text
- View/download PDF
37. No cognitive‐enhancing effect of GLP ‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia
- Author
-
Ishøy, P. L., primary, Fagerlund, B., additional, Broberg, B. V., additional, Bak, N., additional, Knop, F. K., additional, Glenthøj, B. Y., additional, and Ebdrup, B. H., additional
- Published
- 2017
- Full Text
- View/download PDF
38. Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis
- Author
-
Glenthøj, L. B., primary, Jepsen, J. R. M., additional, Hjorthøj, C., additional, Bak, N., additional, Kristensen, T. D., additional, Wenneberg, C., additional, Krakauer, K., additional, Nordentoft, M., additional, and Fagerlund, B., additional
- Published
- 2016
- Full Text
- View/download PDF
39. Mucormycosis in Australia: Contemporary epidemiology and outcomes
- Author
-
Kennedy, K.J., Daveson, K., Slavin, M.A., van Hal, S.J., Sorrell, T.C., Lee, A., Marriott, D.J., Chapman, B., Halliday, C.L., Hajkowicz, K., Athan, E., Bak, N., Cheong, E., Heath, C.H., Morrissey, C.O., Kidd, S., Beresford, R., Blyth, C., Korman, T.M., Robinson, J.O., Meyer, W., Chen, S.C.-A., Clark, J., McCormack, J., Looke, D., Playford, E.G., Chen, S., Gottlieb, T., Halliday, C., Marriott, D., McMullan, B., Sorrell, T., van Hal, S., Ananda-Rajah, M., Slavin, M., Arthur, I., Heath, C., Kennedy, K., Morris, A., Chambers, S., Kennedy, K.J., Daveson, K., Slavin, M.A., van Hal, S.J., Sorrell, T.C., Lee, A., Marriott, D.J., Chapman, B., Halliday, C.L., Hajkowicz, K., Athan, E., Bak, N., Cheong, E., Heath, C.H., Morrissey, C.O., Kidd, S., Beresford, R., Blyth, C., Korman, T.M., Robinson, J.O., Meyer, W., Chen, S.C.-A., Clark, J., McCormack, J., Looke, D., Playford, E.G., Chen, S., Gottlieb, T., Halliday, C., Marriott, D., McMullan, B., Sorrell, T., van Hal, S., Ananda-Rajah, M., Slavin, M., Arthur, I., Heath, C., Kennedy, K., Morris, A., and Chambers, S.
- Abstract
Mucormycosis is the second most common cause of invasive mould infection and causes disease in diverse hosts, including those who are immuno-competent. We conducted a multicentre retrospective study of proven and probable cases of mucormycosis diagnosed between 2004–2012 to determine the epidemiology and outcome determinants in Australia. Seventy-four cases were identified (63 proven, 11 probable). The majority (54.1%) were caused by Rhizopus spp. Patients who sustained trauma were more likely to have non-Rhizopus infections relative to patients without trauma (OR 9.0, p 0.001, 95% CI 2.1–42.8). Haematological malignancy (48.6%), chemotherapy (42.9%), corticosteroids (52.7%), diabetes mellitus (27%) and trauma (22.9%) were the most common co-morbidities or risk factors. Rheumatological/autoimmune disorders occurred in nine (12.1%) instances. Eight (10.8%) cases had no underlying co-morbidity and were more likely to have associated trauma (7/8; 87.5% versus 10/66; 15.2%; p <0.001). Disseminated infection was common (39.2%). Apophysomyces spp. and Saksenaea spp. caused infection in immuno-competent hosts, most frequently associated with trauma and affected sites other than lung and sinuses. The 180-day mortality was 56.7%. The strongest predictors of mortality were rheumatological/autoimmune disorder (OR = 24.0, p 0.038 95% CI 1.2–481.4), haematological malignancy (OR = 7.7, p 0.001, 95% CI 2.3–25.2) and admission to intensive care unit (OR = 4.2, p 0.02, 95% CI 1.3–13.8). Most deaths occurred within one month. Thereafter we observed divergence in survival between the haematological and non-haematological populations (p 0.006). The mortality of mucormycosis remains particularly high in the immuno-compromised host. Underlying rheumatological/autoimmune disorders are a previously under-appreciated risk for infection and poor outcome.
- Published
- 2016
40. Mucormycosis in Australia: contemporary epidemiology and outcomes
- Author
-
Kennedy, K.J., primary, Daveson, K., additional, Slavin, M.A., additional, van Hal, S.J., additional, Sorrell, T.C., additional, Lee, A., additional, Marriott, D.J., additional, Chapman, B., additional, Halliday, C.L., additional, Hajkowicz, K., additional, Athan, E., additional, Bak, N., additional, Cheong, E., additional, Heath, C.H., additional, Morrissey, C.O., additional, Kidd, S., additional, Beresford, R., additional, Blyth, C., additional, Korman, T.M., additional, Robinson, J.O., additional, Meyer, W., additional, Chen, S.C.-A., additional, Clark, Julia, additional, McCormack, Joseph, additional, Looke, David, additional, Playford, E. Geoffrey, additional, Chen, Sharon, additional, Gottlieb, Thomas, additional, Halliday, Catriona, additional, Marriott, Deborah, additional, McMullan, Brendan, additional, Meyer, Wieland, additional, Sorrell, Tania, additional, van Hal, Sebastian, additional, Ananda-Rajah, Michelle, additional, Morrissey, C. Orla, additional, Slavin, Monica, additional, Bak, Narin, additional, Kidd, Sarah, additional, Arthur, Ian, additional, Blyth, Christopher, additional, Heath, Christopher, additional, Kennedy, Karina, additional, Daveson, Kathryn, additional, Morris, Arthur, additional, and Chambers, Steve, additional
- Published
- 2016
- Full Text
- View/download PDF
41. What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore.
- Author
-
Holland D., Sowden D., Everts R., Lee L.-y., Wolfgang J., Day T., Silva G.D., Martinello M., Gliddon T., Wilson M., Athan E., Pollard J., Harris P., Pachchigar R., Wehrhahn M., Moriarty P., Langlands A., McBride S., Sherif M., Lim K., Choong K., Henderson A., Manon M., Sud A., Read K., Yap R., Bursle E., Gluer R., Siebert D., Cross G., Francis J., Booth C., Dalton S., Ooi E.L., Chih D., Dyer J., Clarke J., Grimwood K., Gwee A., Commons R., Majumdar S., Warren S., Manners D., Raby E., Radhakrishnan D., Keighley C., Dotel R., Paterson D., Best E., Aung A.K., Paterson T., Hassell M., Newcombe J., Llorin R., Lye D., Giola M., Yew H.S., Taylor J., Iredell J., Pollett S., Garg L., Jennings Z., Kapur A., Miyakis S., Parshuramkar D., Thu K.M., Rasiah K., Bak N., Chen S., Cooley L., Gordon D., Howden B., McBryde E., Murdoch D., Peleg A., Ralph A., Robinson O., Slavin M., Sorrell T., Tong S., Woolley I., Ingram P.R., Murray R.J., Cheng A.C., Blyth C.C., Walls T., Fisher D.A., Davis J.S., Abbott I., Kanapathipillai R., Madigan V., McLellan D., Briggs S., King C., Hurley J., Lim L.-L., Kennedy K., Wilson H., Evans T., Maze M., Pithie A., Chong L., Leung G., McCann S., Holland D., Sowden D., Everts R., Lee L.-y., Wolfgang J., Day T., Silva G.D., Martinello M., Gliddon T., Wilson M., Athan E., Pollard J., Harris P., Pachchigar R., Wehrhahn M., Moriarty P., Langlands A., McBride S., Sherif M., Lim K., Choong K., Henderson A., Manon M., Sud A., Read K., Yap R., Bursle E., Gluer R., Siebert D., Cross G., Francis J., Booth C., Dalton S., Ooi E.L., Chih D., Dyer J., Clarke J., Grimwood K., Gwee A., Commons R., Majumdar S., Warren S., Manners D., Raby E., Radhakrishnan D., Keighley C., Dotel R., Paterson D., Best E., Aung A.K., Paterson T., Hassell M., Newcombe J., Llorin R., Lye D., Giola M., Yew H.S., Taylor J., Iredell J., Pollett S., Garg L., Jennings Z., Kapur A., Miyakis S., Parshuramkar D., Thu K.M., Rasiah K., Bak N., Chen S., Cooley L., Gordon D., Howden B., McBryde E., Murdoch D., Peleg A., Ralph A., Robinson O., Slavin M., Sorrell T., Tong S., Woolley I., Ingram P.R., Murray R.J., Cheng A.C., Blyth C.C., Walls T., Fisher D.A., Davis J.S., Abbott I., Kanapathipillai R., Madigan V., McLellan D., Briggs S., King C., Hurley J., Lim L.-L., Kennedy K., Wilson H., Evans T., Maze M., Pithie A., Chong L., Leung G., and McCann S.
- Abstract
The practice of an infectious diseases (ID) physician is evolving. A contemporary understanding of the frequency and variety of patients and syndromes seen by ID services has implications for training, service development and setting research priorities. We performed a 2-week prospective survey of formal ID physician activities related to direct inpatient care, encompassing 53 hospitals throughout Australia, New Zealand and Singapore, and documented 1722 inpatient interactions. Infections involving the skin and soft tissue, respiratory tract and bone/joints together accounted for 49% of all consultations. Suspected/confirmed pathogens were primarily bacterial (60%), rather than viral (6%), fungal (4%), mycobacterial (2%) or parasitic (1%). Staphylococcus aureus was implicated in 409 (24%) episodes, approximately four times more frequently than the next most common pathogen. The frequency of healthcare-related infections (35%), immunosuppression (21%), diabetes mellitus (19%), prosthesis-related infections (13%), multiresistant pathogens (13%) and non-infectious diagnoses (9%) was high, although consultation characteristics varied between geographical settings and hospital types. Our study highlights the diversity of inpatient-related ID activities and should direct future teaching and research. ID physicians' ability to offer beneficial consultative advice requires broad understanding of, and ability to interact with, a wide range of referring specialities.Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases.
- Published
- 2015
42. Information Technology in the Health Sector: improving service delivery and public trust
- Author
-
Gibson, D.M., Askvik, S., Bak, N., and Health, care and the body (ASSR, FMG)
- Published
- 2004
43. Antifungal therapy and management of Complications of cryptococcosis due to Cryptococcus gattii
- Author
-
Chen, Sharon, Korman, Tony, Slavin, Monica, Marriott, Debbie, Byth, Karen, Bak, N., Currie, Bart J., Hajkowicz, Krispin, Heath, Christopher, Kidd, Sarah, McBride, William, Meyer, Wieland, Murray, Ronan J., Playford, Geoffrey, Sorrell, Tania, Chen, Sharon, Korman, Tony, Slavin, Monica, Marriott, Debbie, Byth, Karen, Bak, N., Currie, Bart J., Hajkowicz, Krispin, Heath, Christopher, Kidd, Sarah, McBride, William, Meyer, Wieland, Murray, Ronan J., Playford, Geoffrey, and Sorrell, Tania
- Published
- 2013
44. Clinical Manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death
- Author
-
Chen, Sharon, Slavin, Monica, Heath, Christopher, Playford, Geoffrey, Byth, Karen, Marriott, Debbie, Kidd, Sarah, Bak, N., Currie, Bart J., Hajkowicz, Krispin, Korman, Tony, McBride, William, Meyer, Wieland, Murray, Ronan J., Sorrell, Tania C., Chen, Sharon, Slavin, Monica, Heath, Christopher, Playford, Geoffrey, Byth, Karen, Marriott, Debbie, Kidd, Sarah, Bak, N., Currie, Bart J., Hajkowicz, Krispin, Korman, Tony, McBride, William, Meyer, Wieland, Murray, Ronan J., and Sorrell, Tania C.
- Published
- 2012
45. Treatment Outcomes for Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility.
- Author
-
Ward P.B., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D.R., Morris A.J., Mayall B.C., Grayson M.L., Korman T.M., Charles P.G.P., Howden B.P., Fuller A., Du Cros P., Ward P.B., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D.R., Morris A.J., Mayall B.C., Grayson M.L., Korman T.M., Charles P.G.P., Howden B.P., Fuller A., and Du Cros P.
- Abstract
Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.
- Published
- 2012
46. Cryptococcus gattii infection: Long term morbidity and determinants of neurological sequelae and death.
- Author
-
McBride W.J., Korman T., Meyer W., Sorrell T., Murray R., Chen S., Slavin M., Heath C., Playford E.G., Byth K., Marriott D., Kidd S., Bak N., Currie B., Hajkowicz K., McBride W.J., Korman T., Meyer W., Sorrell T., Murray R., Chen S., Slavin M., Heath C., Playford E.G., Byth K., Marriott D., Kidd S., Bak N., Currie B., and Hajkowicz K.
- Abstract
Background: Long-term morbidity and outcomes of Cryptococcus gattii (CG) infection are not described. We analysed clinical, microbiological and outcome data in Australian patients followed for 12 months to identify determinants of mortality and patient outcomes, and to inform clinical management. Method(s): Culture-confirmed cases from 2000-2007 were evaluated in an observational study. Clinical presentation, complications, microbiological, radiological and outcome data were recorded at diagnosis and at 6 weeks, 6 months and 12 months. Clinical and laboratory variables associated with mortality and with death and/or neurological sequelae were determined. Result(s): The annual CG infection incidence was 0.61/106 population. Fifty-four patients had no immunocompromise/comorbidity. Of 24 (28%) immunocompromised hosts, six had idiopathic CD4 lymphopenia and one, HIV/AIDS. Clinical and microbiological characteristics of infection were similar in immunocompromised and healthy hosts. Central nervous system (CNS) manifestations, present in 85% of patients, included raised intracranial pressure (41%), hydrocephalus (30%), neurological deficits (27%; 6% developed during therapy) and immune reconstitution syndrome (11%). Geometric mean serum cryptococcal antigen (CRAG) titres in CNS disease were 563.9 (vs. 149.3 in isolated lung infection). Immunocompromise and intensive care admission were risks for death. Initial cerebrospinal fluid CRAG titres of >=256 predicted death and/or neurological sequelae (P = .05). Conclusion(s): Neurological disease predominates in sporadic CG infection. Lumbar puncture and cerebral imaging, especially if serum CRAG titres are >=512, are essential. Long-term follow-up is required to detect late neurological complications. Immune system evaluation is important since host immunocompromise (and intensive care admission) was associated with reduced survival.
- Published
- 2012
47. Undiagnosed and potentially lethal parasite infections among immigrants and refugees in Australia
- Author
-
Caruana, SR, Kelly, HA, Ngeow, JYY, Ryan, NJ, Bennett, CM, Chea, L, Nuon, S, Bak, N, Skull, SA, Biggs, B-A, Caruana, SR, Kelly, HA, Ngeow, JYY, Ryan, NJ, Bennett, CM, Chea, L, Nuon, S, Bak, N, Skull, SA, and Biggs, B-A
- Abstract
Intestinal parasite infections are a major cause of ill health in many resource-poor countries. This study compares the types and rates of these infections and their risk factors in recently arrived and long-term immigrants in Australia. Cross-sectional surveys of 127 East African and 234 Cambodian immigrants and refugees were undertaken in 2000 and 2002, respectively, to assess the burden of intestinal parasites and collect demographic information. Serum samples were assessed for eosinophilia and Strongyloides stercoralis and Schistosoma antibodies, and feces examined for ova, cysts, and parasites. Intestinal parasites were identified in 77/117 fecal samples from East African and in 25/204 samples collected from Cambodian participants. Eleven percent (14/124) of East Africans and 42% (97/230) of Cambodians had positive or equivocal serology for S stercoralis. Schistosoma serology was positive or equivocal in 15% (19/124) of East African participants. Potentially serious intestinal parasite infections are common among recent and longer term immigrants despite multiple visits to health care providers. Immigrants and refugees from high-risk countries would benefit from comprehensive health checks soon after resettlement.
- Published
- 2006
48. Antibiotic prescribing in response to bacterial isolates in the intensive care unit
- Author
-
Buising, K., Thursky, K., Bak, N., Skull, Susan, Street, A., Presneill, J., Cades, J., Brown, G., Buising, K., Thursky, K., Bak, N., Skull, Susan, Street, A., Presneill, J., Cades, J., and Brown, G.
- Abstract
This study aimed to identify potential knowledge-performance gaps in antibiotic prescribing for bacterial isolates in the Intensive Care Unit (ICU) in order to guide the development of interventions such as antibiotic policies, decision support, and improved systems for communication between the laboratory and the bedside. A prospective observational cohort study of all patients admitted to a mixed medical/surgical ICU was undertaken over a six-month period in an Australian adult tertiary hospital. From a cohort of 524 patients, 108 had 303 isolates that were eligible for inclusion. Overall, 14.3% and 30.8% of sterile and non-sterile isolates respectively were associated with inadequate initial antibiotic therapy after identification of the bacteria. After sensitivity results were available inadequate directed therapy was observed in 4.0% and 21.3% of sterile and non-sterile isolates respectively. Problems were most commonly associated with isolates of Pseudomonas spp., Stenotrophomonas spp., Acinetobacter spp., S. aureus, enterococci and group III Enterobacteriaceae. Inadequate antibiotic therapy was found to be independently associated with prolonged length of ICU stay. Narrower spectrum antibiotic therapy was potentially available for 30% of isolates after sensitivity results were known. We conclude that there is scope to improve antibiotic prescribing in the ICU by providing clinicians with access to information regarding local susceptibility patterns and intrinsic resistance of bacteria, and spectra of antibiotic cover. Timely notification of laboratory results at the point of care may also facilitate improved prescribing performance.
- Published
- 2005
49. Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the Mekong Region
- Author
-
Caruana, SR, Kelly, HA, De Silva, SL, Chea, L, Nuon, S, Saykao, P, Bak, N, Biggs, BA, Caruana, SR, Kelly, HA, De Silva, SL, Chea, L, Nuon, S, Saykao, P, Bak, N, and Biggs, BA
- Abstract
OBJECTIVE: Infection with hepatitis B (HBV) and hepatitis C (HCV) viruses is relatively common throughout South-East Asia and chronic infection can lead to severe consequences. This study assesses knowledge about HBV and HCV and estimates the seroprevalence of markers for these viruses in immigrants from Laos and Cambodia. METHODS: Ninety-five Laotian (aged 18-82 years) and 234 Cambodian (15-92 years) immigrants participated in separate community-based surveys conducted during 1998 and 2002, respectively. Participants completed a questionnaire on health status and level of knowledge about viral hepatitis. Blood samples were collected and tested for the presence of HBV and HCV markers. RESULTS: Nine per cent of Laotian and 8% of Cambodian participants were infected with HBV. While 49% of Laotian and 64% of Cambodian participants showed evidence of previous exposure to HBV, 30% and 9%, respectively, were vulnerable to infection. The seroprevalence of antibodies to HCV was 3% in the Laotian and 8% in the Cambodian participants. Between one-fifth and one-third of the Laotians and Cambodians who had heard of HBV and HCV knew of possible transmission routes for the viruses. Most of those with HBV or HCV infection were unaware they were infected. CONCLUSIONS: These findings indicate a significant prevalence of undetected HBV and HCV infections and an urgent need for the provision of culturally relevant information about viral hepatitis in immigrants of South-East Asian origin.
- Published
- 2005
50. Antibiotic Prescribing in Response to Bacterial Isolates in the Intensive Care Unit
- Author
-
Buising, K. L., primary, Thursky, K. A., additional, Bak, N., additional, Skull, S., additional, Street, A., additional, Presneill, J. J., additional, Cade, J. F., additional, and Brown, G. V., additional
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.